TSHA-102 – Talk Bio

Actionable Insights Powered by AI

Kezar Initiates Strategic Review After FDA Setback; Taysha Regains Full Rights to Rett Syndrome Program as Astellas Agreement Ends

6 days ago talkbio0Tagged Astellas, Autoimmune Chronic Hepatitis, Clinical Trials, Kezar Life Sciences, Rett Syndrome, setback, strategic alternatives, Taysha Gene Therapies, TSHA-102, United States Food and Drug Administration, Zetomipzomib

Kezar Life Sciences; FDA setback; strategic alternatives; zetomipzomib; autoimmune hepatitis; Taysha Gene Therapies; Astellas; Rett syndrome; TSHA-102; clinical trials

Taysha Gene Therapies Announces Positive Results for TSHA-102 in Rett Syndrome Trials

1 year ago talkbio0Tagged autonomic function, Communication, gene therapy, Motor Skills, Rett Syndrome, Seizures, Taysha Gene Therapies, TSHA-102

Taysha Gene Therapies, TSHA-102, Rett Syndrome, Gene Therapy, Motor Skills, Communication, Autonomic Function, Seizures